Skip to main content

Rural Intermediate Care Hospitalizations Tied to Worse Outcomes

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 8, 2024.

By Lori Solomon HealthDay Reporter

THURSDAY, Feb. 8, 2024 -- Hospitalization in rural intermediate care is associated with increased mortality, according to a study published online Jan. 19 in the Annals of the American Thoracic Society.

Emily A. Harlan, M.D., from the University of Michigan in Ann Arbor, and colleagues examined relationships of rurality and location of care with mortality for roughly 2.75 million Medicare beneficiaries (65 years and older) who received invasive mechanical ventilation between 2010 to 2019.

The researchers found that 7.0 percent of patients were treated in rural hospitals. During the study period, the proportion of patients in rural intermediate care increased from 4.1 to 6.3 percent, while patient admissions to urban hospitals remained relatively stable. Adjusted 30-day mortality was similar for patients in rural and urban intensive care units (46.7 percent; adjusted absolute risk difference, −0.1). For patients in rural intermediate care, adjusted 30-day mortality was significantly higher compared with patients in urban intermediate care (37.0 versus 31.3 percent; adjusted absolute risk difference, 5.6 percent).

"There is a need to better understand how intermediate care is used across hospitals and to carefully evaluate the types of patients admitted to intermediate care units," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.